What is the recommended treatment regimen for Brucella infection involving the bone marrow?

Treatment of Brucella with Bone Marrow Involvement

For Brucella infection with bone marrow involvement, treat with doxycycline 100 mg twice daily for 6 weeks combined with streptomycin 15 mg/kg daily intramuscularly for 2-3 weeks, or substitute gentamicin 5 mg/kg daily parenterally for 7 days if streptomycin is unavailable. 1

Recommended Treatment Regimens

The Ioannina recommendations provide clear guidance for brucellosis treatment, which applies to bone marrow involvement as this represents a serious hematologic complication:

First-Line Options (in order of preference):

1. Doxycycline + Streptomycin (DOX-STR):

   • Doxycycline 100 mg twice daily orally for 6 weeks
   • Streptomycin 15 mg/kg daily intramuscularly for 2-3 weeks
   • This is the gold standard with the lowest relapse rates 1, 2

2. Doxycycline + Gentamicin (DOX-GENT):

   • Doxycycline 100 mg twice daily orally for 6 weeks
   • Gentamicin 5 mg/kg daily parenterally for 7 days
   • Acceptable alternative with comparable efficacy 1
   • Gentamicin is more widely available than streptomycin

3. Doxycycline + Rifampicin (DOX-RIF):

   • Doxycycline 100 mg twice daily orally for 6 weeks
   • Rifampicin 600-900 mg daily for 6 weeks
   • Has significantly higher relapse rates (relative risk 2.80) compared to DOX-STR 2
   • Should be considered second-line despite oral convenience

Special Considerations for Bone Marrow Involvement

The case report of an 11-year-old with brucellosis-induced bone marrow aplasia demonstrates successful treatment with triple therapy initially: doxycycline + rifampicin + gentamicin, with gentamicin discontinued after 3 weeks, followed by 8 months total treatment duration 3. This suggests:

• Consider triple therapy (doxycycline + rifampicin + aminoglycoside) for severe bone marrow involvement 4
• Extend treatment duration beyond standard 6 weeks when bone marrow is severely affected
• Monitor hematologic recovery closely

Critical Treatment Principles

Duration matters: Treatment for 6 weeks or more offers significant advantage over shorter durations 2. For bone marrow involvement specifically, consider extending therapy to 8-12 weeks based on clinical response 3.

Combination therapy is mandatory: Monotherapy has unacceptably high relapse rates (13% vs. 4.8% for combination therapy) 5. The relative risk of failure with monotherapy is 2.56 compared to combination treatment 2.

Aminoglycosides provide superior outcomes: Meta-analysis confirms that doxycycline-streptomycin results in significantly lower overall failure rates than doxycycline-rifampicin, primarily due to reduced relapse (RR 2.80 for DOX-RIF vs DOX-STR) 2. The most recent network meta-analysis ranks doxycycline + gentamicin as most efficacious (SUCRA 0.94), followed by triple therapy (SUCRA 0.87) and doxycycline + streptomycin (SUCRA 0.78) 4.

Common Pitfalls to Avoid

• Don't use quinolone-based regimens as first-line: They have significantly higher failure rates (RR 1.83) compared to standard regimens 2
• Don't shorten aminoglycoside duration excessively: While 5-7 days of gentamicin may be adequate for uncomplicated cases, bone marrow involvement may warrant 2-3 weeks 1
• Don't rely on rifampicin combinations alone: Despite oral convenience, they have demonstrably higher relapse rates 2, 6
• Don't stop treatment prematurely: Even if hematologic parameters normalize, complete the full 6-week minimum course to prevent relapse

Monitoring and Follow-up

• Serial complete blood counts to assess bone marrow recovery
• Follow-up serology at treatment completion and 3-6 months post-treatment
• Watch for relapse symptoms up to 12 months after treatment completion 3
• If platelet count drops below 10,000/mm³, consider adding corticosteroids and IVIG to antimicrobial therapy 7